Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (119)

« Back to Publications

Toward Integration of Molecular Measures and Artificial Intelligence-Based Assessments With Clinical End Points in Inflammatory Bowel Disease

Reinisch W. et al, (2026), Gastroenterology, 170, 686 - 703

CD4+ tissue-resident memory Th17 cells are a major source of IL-17A in Spondyloarthritis synovial tissue.

Liu F. et al, (2025), Annals of the rheumatic diseases, 84, 1151 - 1163

Global Practices in Cardiac Imaging for Cardiac Sarcoidosis: A Survey Study of International Experts With Delphi Consensus.

Kafil TS. et al, (2025), JACC. Cardiovascular imaging, 18, 679 - 692

Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy

Tadros R. et al, (2025), Nature Genetics, 57, 530 - 538

XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.

Woelfel S. et al, (2025), Alimentary pharmacology & therapeutics, 61, 299 - 312

Molecular signature of bowel urgency in Ulcerative Colitis

Pakpoor J. et al, (2025), JOURNAL OF CROHNS & COLITIS, 19, i583 - i585

DEVELOPMENT OF THE INTCAL DATABASE

Bronk Ramsey C. et al, (2024), Radiocarbon, 66, 1852 - 1868

Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy.

Tahir UA. et al, (2024), Circulation. Heart failure, 17

A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease

Thomas T. et al, (2024), Nature Immunology, 25, 2152 - 2165

STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.

Woelfel S. et al, (2024), Vaccines, 12

Cardiovascular Magnetic Resonance Reference Ranges From the Healthy Hearts Consortium.

Raisi-Estabragh Z. et al, (2024), JACC. Cardiovascular imaging, 17, 746 - 762

Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease.

Woelfel S. et al, (2024), Vaccines, 12

MHC class II antigen presentation by intestinal epithelial cells fine-tunes bacteria-reactive CD4 T-cell responses

Heuberger CE. et al, (2024), Mucosal Immunology, 17, 416 - 430

STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.

Woelfel S. et al, (2023), Alimentary pharmacology & therapeutics, 58, 678 - 691

Platelet‐derived lipids promote insulin secretion of pancreatic β cells

Karwen T. et al, (2023), EMBO Molecular Medicine, 15

Load More

1
2
3
4
5
6
7
...
»